NAGE — Niagen Bioscience Balance Sheet
0.000.00%
- $520.34m
- $460.02m
- $99.60m
- 69
- 34
- 69
- 60
Annual balance sheet for Niagen Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 16.7 | 28.2 | 20.2 | 27.2 | 44.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.69 | 5.23 | 8.48 | 5.23 | 7.77 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 32.2 | 48.9 | 46.6 | 49.5 | 64.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.43 | 7.36 | 6.32 | 4.54 | 3.45 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 38.4 | 57.8 | 54.1 | 55 | 68.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 16.5 | 17.6 | 17.9 | 20.6 | 17.9 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 21.9 | 26.1 | 25.4 | 26.5 | 22.2 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 16.4 | 31.7 | 28.7 | 28.5 | 46.1 |
| Total Liabilities & Shareholders' Equity | 38.4 | 57.8 | 54.1 | 55 | 68.3 |
| Total Common Shares Outstanding |